In December 2024, the FDA abruptly determined that the tirzepatide shortage had resolved and removed these products from its shortage list, effectively terminating compounders' legal authority to produce these drugs
By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide
There is currently no published research exploring the relationship between semaglutide and the effectiveness of oral birth control
It works by decreasing the number of cells the skin makes and regulates overgrowth of skin cells
Interestingly, the defendants supported this motion, likely to avoid fragmented litigation across the country
The foundation of RejuveMe is OPITAC glutathione from Japan